Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Orion Oyj

Orion Corporation focuses on developing and manufacturing pharmaceutical products and self-described well-being solutions, including medicines and therapies in areas such as pain, cancer, and respiratory diseases.

msh id	FI:ORION
symbol	ORNAV
name	Orion Oyj
homepage url	https://www.orion.fi
country	FI
sector	Healthcare
industry	Drug Manufacturers - General
market	STOCKS
employee count	3.7K
crunchbase url	-
linkedin url	-
founders	-

market cap	6.23B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.06
growth cost of revenue	0.08
growth depreciation and amortization	0.04
growth ebitda	-0.42
growth ebitda ratio	-0.35
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.09
growth gross profit	-0.23
growth gross profit ratio	-0.13

FI:ORION

Orion Corporation

Last Close

44.30

21/11 16:29

Market Cap

5.77B

Beta: -

Volume Today

3.07K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	1.03B
cost of revenue	1.03B
depreciation and amortization	55.6M
ebitda	305.32M
ebitda ratio	0.24
eps	1.67
eps diluted	1.66
operating expenses	460.46M
operating income	249.72M
operating income ratio	0.19

accounts receivables	-96.09M
capital expenditure	-126.1M
cash at beginning of period	359.08M
cash at end of period	115.2M
inventory	391.04M
working capital ttm	480.7M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-